Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by multicoreon Oct 31, 2010 9:17pm

548 Views

Post# 17637672

Updated Information?

The following is old information as it is dated June 30, 2010. It does support what has already been stated on this forum about the degree of involvement of Sprott in QEI. The data from Stockwatch has probably changed since that date but it is quite impressive to see that one investment firm has put a small stock like this into 5 of their funds.

Sprott Asset Management LP
Sprott Growth Fund
Sprott Small Cap Equity
Sprott Canadian Equity Fund
Sprott All Capital Fund
Does anyone have any information which is newer than June 30th?

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features